

#8

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wheeler et al)

Serial No.: 10/020,541)

Conf. No.: 1687)

Filed: October 30, 2001)

For: METHODS AND COMPOSITIONS)
FOR TREATMENT OF OCULAR)
NEOVASCULARIZATION AND)
NEURAL INJURY)

Examiner: Not Assigned)

Group Art Unit: Not Assigned)

I hereby certify that this correspondence is being filed by First Class Mail
in an envelope addressed to: U.S. Patent and Trademark Office, Box
Sequence, P.O. Box 2327, Washington, D.C. 20231 on:

Date of Deposit: 4/23/2002

BONNIE FERGUSON
Print Name

Signature: Bonnie Ferguson

Date of Signature: 4/23/2002

SEQUENCE LISTING STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir,

Applicant affirms that the Computer Readable Copy of the Sequence Listing, submitted herewith, is the same as the paper copy of the Sequence Listing, also submitted herewith. No new matter has been added to the Application as a result of the submission of the Sequence Listing. This statement is submitted as required by 37 CFR 1.821(f).

No fee is believed due in connection with this communication. However, if Applicants are in error, the Commissioner is hereby authorized to charge Deposit Account No. 07-0835 the appropriate fees.

Respectfully submitted,

Date: 4/22/02

Carlos A. Fisher

Carlos A. Fisher
Registration No. 36,510
ALLERGAN, INC.
T2-7H
Legal Department
2525 Dupont Drive
Irvine, CA. 92612
Tel: (714) 246-4920
Fax: (714) 246-4249

RECEIVED

APR 30 2002

OFFICE OF PETITIONS



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 26 2002

APR - 2 2002

 RECEIVED
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/020,544 TRADEMARK	10/30/2001	Larry A. Wheeler	17400(BAR)

Carlos A. Fisher
 ALLERGAN, INC.
 T2-7H
 2525 Dupont Drive
 Irvine, CA 92612

RECEIVED

APR 30 2002

OFFICE OF PETITIONS

CONFIRMATION NO. 1687

FORMALITIES LETTER



OC000000007719169

Date Mailed: 03/26/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

The following item(s) appear to have been **omitted** from the application:

- Page(s) **14** of the specification (description and claims).

I. Should applicant contend that the above-noted omitted item(s) was in fact deposited in the U.S. Patent and Trademark Office (USPTO) with the nonprovisional application papers, a copy of this Notice and a petition (and

\$130.00 petition fee (37 CFR 1.17(h))) with evidence of such deposit **must** be filed within **TWO MONTHS** of the date of this Notice. The petition fee will be refunded if it is determined that the item(s) was received by the USPTO.

II. Should applicant desire to supply the omitted item(s) and accept the date that such omitted item(s) was filed in the USPTO as the filing date of the above-identified application, a copy of this Notice, the omitted item(s) (with a supplemental oath or declaration in compliance with 37 CFR 1.63 and 1.64 referring to such items), and a petition under 37 CFR 1.182 (with the \$130.00 petition fee (37 CFR 1.17(h)) requesting the later filing date **must** be filed within **TWO MONTHS** of the date of this Notice.

III. The failure to file a petition (and petition fee) under the above options (I) or (II) within **TWO MONTHS** of the date of this Notice (37 CFR 1.181(f)) will be treated as a constructive acceptance by the applicant of the application as deposited in the USPTO. **THIS TWO MONTH PERIOD IS NOT EXTENDABLE UNDER 37 CFR 1.136(a) or (b)**. In the absence of a timely filed petition in reply to this Notice, the application will maintain a filing date as of the date of deposit of the application papers in the USPTO, and original application papers (i.e., the original disclosure of the invention) will include only those application papers present in the USPTO on the date of deposit.

In the event that applicant elects not to take action pursuant to options (I) or (II) above (thereby constructively electing option (III)), amendment of the specification to renumber the pages consecutively and cancel incomplete sentences caused by any omitted page(s), and/or amendment of the specification to cancel all references to any omitted drawing(s), relabel the drawing figures to be numbered consecutively (if necessary), and correct the references in the specification to the drawing figures to correspond with any relabelled drawing figures, is required. Any drawing changes should be accompanied by a copy of the drawing figures showing the proposed changes in red ink. Such amendment and/or correction to the drawing figures, if necessary, should be by way of preliminary amendment submitted prior to the first Office action to avoid delays in the prosecution of the application.

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

RECEIVED

APR 3 0 2002

OFFICE OF PETITIONS